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A B S T R A C T
The development of hematopoietic stem cell transplantation (HSCT) programs can face signiﬁcant challenges in
most developing countries because such endeavors must compete with other government health care priorities,
including the delivery of basic services. Although this is may be a limiting factor, these countries should prioritize
development of the needed expertise to offer state-of-the-art treatments, including transplantation, by providing
ﬁnancial, technological, legal, ethical, and other needed support. This would prove beneﬁcial in providing successful programs customized to the needs of their population and potentially provide long-term cost savings by circumventing the need for their citizens to seek care abroad. The costs of establishing an HSCT program and the
costs of the HSCT procedure itself can be substantial barriers in developing countries. In addition, socioeconomic
factors intrinsic to speciﬁc countries can inﬂuence access to HSCT, patient eligibility for HSCT, and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood
and Marrow Transplantation for establishing HSCT programs, with a speciﬁc focus on developing countries, and
identiﬁes challenges and opportunities for providing this specialized procedure in resource-constrained settings.
© 2019 The Author(s). Published by Elsevier Ltd. on behalf of King Faisal Specialist Hospital & Research Centre and
Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. This is an open access
article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

INTRODUCTION
The establishment of hematopoietic stem cell transplantation
(HSCT) programs in developing countries can enhance and
improve tertiary care health services. There are various positive
attributes that favor the establishment of such a high-proﬁle venture; however, there are also signiﬁcant obstacles to be addressed.
Because the obvious issue in most economies is cost distribution and budget allocations for healthcare, public health measures
take precedence over noncommunicable chronic diseases. However, over time, there has been an increasing focus on chronic diseases, particularly cancers, which have become the leading cause
of mortality in both developing and developed nations. There has
been an exponential growth in both the prevalence and incidence
of diseases that can be cured by HSCT, including sickle cell anemia, thalassemia, leukemia, myeloma, lymphoma, immunodeﬁciencies, and metabolic disorders. As a result, many new HSCT
centers have been opening in developing nations.
In most developing countries, a HSCT program must compete for allocation of limited funds with other priorities for
basic health care services, such as food, sanitation, immunization, population control, and communicable disease prevention. Nonetheless, developing countries should have the
expertise to offer state-of-the-art treatments, including HSCT,
to enable treatment locally at a much lower cost than abroad.
The most important step in this effort is providing ﬁnancial,
technological, legal, ethical, and other support for local individuals and institutions to proactively establish new HSCT programs. The goals include to develop a customized local
experience tailored to each developing country and also to
allow local dissemination of this experience as it evolves [1].
When establishing a HSCT program in a developing country, ﬁnancial, technological, logistic, and social challenges, as
well as the availability of skilled manpower, are all potential
difﬁculties that should be taken into consideration. Given the
exponential growth in both the number of HSCTs performed
worldwide and the establishment of new HSCT centers in both
high- and low-income countries, the Worldwide Network for
Blood and Marrow Transplantation (WBMT) has recognized
the need to provide guidance to institutions and individuals
considering opening a new HSCT center. Part I of this report
describes the absolute minimum, minimum, preferred, and
ideal requirements for the establishment of a new HSCT program. Here in Part II, we address clinical, technical, and ﬁnancial considerations for establishing an HSCT program in the
resource-constrained setting typical in developing countries.

Financial Issues and Costs of Establishing an HSCT Program
HSCT remains a highly specialized, complex, resourceintensive, and costly medical procedure. A 2009 report from
the US Agency for Healthcare Research and Quality identiﬁed
HSCT as among the top 10 procedures with the greatest
increase in hospital costs from 2004 to 2007. Total US national
costs of HSCT hospitalization increased from $694 million to
$1.3 billion over this period [2].
Thus, establishment of a dedicated center for this costly
procedure requires a comprehensive understanding of economic indicators and challenges. There are 4 main economic
evaluations that provide information to guide decision making
on the basis of the value for money: cost minimization, cost
beneﬁt, cost effectiveness, and cost utility.
Cost minimization is commonly practiced in HSCT whenever a lower-cost, equally effective treatment is chosen over
more expensive treatments. A cost-beneﬁt analysis is rarely
used in procedures like transplantation because it requires
assignment of monetary costs to measure clinical beneﬁts,
which are difﬁcult to assign in this complex setting with
potential for long-term cure for a proportion of recipients.
Cost utility analysis is a speciﬁc type of cost-effectiveness
analysis in which outcomes are adjusted to consider healthrelated quality of life, so that a cure without treatment
sequelae is considered more valuable than a cure resulting in
continuing health disabilities [3].
In this article, we emphasize HSCT interventions that focus
primarily on cost-effectiveness or cost utility. To develop a cost
containment program, proof of both clinical and economic
effectiveness is preferred before widespread adoption of new
technologies [4].
It is critical to identify the exact drivers of cost before considering initiation of a HSCT program. Little data are available
for evaluating the exact drivers of HSCT costs in developing
countries. A recent study of establishment of a cancer center
in Rwanda, a developing country, identiﬁed $556,105 as the
necessary startup funding to implement the cancer program
[5]. The annual operating cost of the program was calculated
as $957,203. Radiotherapy, labor, and chemotherapy were
the most signiﬁcant cost drivers; however, radiotherapy
required sending patients out of the country because of the
absence of radiation units in Rwanda. Labor accounted for
21% of the cost, and chemotherapy, supportive medications,
and consumables together accounted for 15%. Although radiation therapy is not routinely performed for HSCT, it is a
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Figure 1. Major determinants of costs in establishment of an HSCT program. MRI indicates magnetic resonance imaging; PET, positron emission tomography; IT,
information technology; EMR, electronic medical record; BM, bone marrow; PRBCs, packed red blood cells; UCB, umbilical cord blood; haplo, haploidentical; RD,
related donor

necessary part of certain preparative regimens, and thus the
establishment of a radiation therapy unit is likely to signiﬁcantly increase costs.
The high costs of HSCT can be attributed to various factors,
as discussed below (Figure 1).

Patient-Related Factors
When designing a national program for HSCT in a developing country, few patient-related factors can be assessed for
opportunities for cost reduction. Although there are no consistent correlations between costs and patient age, sex, performance status, or disease risk, in some more recent studies,
advanced risk disease was a signiﬁcant predictor of higher
costs [6-10].
In view of the limited resources in developing countries,
health authorities should allocate available resources to the
priority areas where low cost inputs yield high dividends.
However, there are no clear recommendations, and each country needs to adopt the policies that best address the needs of
its populations.
Considering the young median patient age in many developing countries, it would be prudent to initially make HSCT
available to younger patients with curable diagnoses and longer lifespan beneﬁts. Subsequently, expanding the eligibility
for HSCT to older patients and patients with advanced disease
may be appropriate as the program develops.

Transplantation Center Experience
Cost reduction and clinical outcomes have been shown to
improve with increasing institutional experience [11]. However, this economic advantage may be offset as the complexity
of treated patients increases and more aggressive supportive
interventions are applied, resulting in a plateau in the
improvement curve [11-13]. Growing local expertise and
adopting cost-effective practices can limit total costs and
improve transplantation outcomes.

Human Resources and Continuous Training
The availability of sufﬁcient well-trained staff at the various
steps of transplantation with continuous training to advance
their knowledge is a cornerstone of any successful transplantation program. Migration of health care professionals from
developing to developed countries deprives the developing
world of valuable and essential human resources [14]. Countries should strengthen health system requirements, including
physical infrastructure and skilled human resources, to meet
the multidisciplinary requirements of HSCT, aiming for high
quality and safety as fundamental principles. International
cooperation and twinning with other institutions in developed
countries could facilitate exchange of expertise across the
globe. Adequate attention for neutropenic and hygienic precautions and any other measures to reduce infection should be
considered.
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Donor Selection and HLA Typing
With the advances in immunogenetics and transplantation
immunology, particularly in the structure and function of the
HLA system in the 1990s, new and efﬁcient technologies for
HLA typing have emerged and progressed [15,16].
According to the guidelines of World Marrow Donor Association and European Federation for Immunogenetics, high-resolution HLA typing should be performed for both HSCT
recipients and donors. HLA typing should also include the
HLA-C locus owing to the recognized role of this locus in graft
rejection [17,18].
The technology for HLA typing has evolved from the serologic level to the cellular level and more recently to the molecular level. Serotyping was the mainstream method for HLA
typing and played a critical role in organ transplantation before
the 1990s. However, most HLA antisera are polyclonal with
lower speciﬁcity and variable sensitivity, and thus molecular
methods to type HLA at the DNA level have replaced serologic
and cellular typing.
Commonly used DNA-based HLA typing methods include
PCR-based sequence-speciﬁc primers (PCR-SSP), PCR-based
restriction fragment length polymorphism (PCR-RFLP), PCRbased single-strand conformation polymorphism (PCR-SSCP),
PCR-based sequence-speciﬁc oligonucleotide (PCR-SSO), and
PCR-based single nucleotide polymorphism (PCR-SNP). PCRSSP genotyping is commonly used for HLA typing in clinical
laboratories worldwide. PCR-SSP and PCR-SSO are associated
with high cost and prolonged operation time and thus are
rarely used for HLA typing at present.
PCR-SNP is a simple and fast method with high resolution
that will become more popular as the technology continues to
improve. At present, PCR sequence-based typing (PCR-SBT)
technology has signiﬁcant advantages over other HLA typing
methods in terms of accuracy, efﬁciency, and automation. In
addition, the operational costs are greatly reduced [15]. It is
recommended that new programs in developing countries
with limited resources should start by performing matched
sibling transplantation, in which high-resolution typing might
not be necessary and some risks are reduced.
Outsourcing HLA typing can be a cost-effective alternative
in developing countries where laboratories with immunogenetic capabilities and expertise are not yet available. Many
companies in developed countries offer molecular-based HLA
typing at competitive prices, particularly for bulk contracts.
Conditioning Intensity
Both the intensity and the duration of conditioning affect
the cost of HSCT. Large studies have conﬁrmed the lower costs
associated with reduced-intensity regimens, with fewer
median hospital days within the ﬁrst year after transplantation
compared with high-dose and myeloablative regimens [8].
Myeloablative allogeneic HSCT is associated with a higher
frequency and severity not only of short-term toxicities, but
also of late complications such as infertility, growth retardation in children, and new primary malignancies. It also may be
associated with increases in the use of blood products, risk of
infections, transplantation-related mortality, and length of
hospital stay. Despite their advantages, lower-intensity regimens must be adapted for important patient- and diseaserelated variables, given a recent multicenter trial showing a
clear advantage in reducing AML relapse with the use of myeloablative regimens in younger, ﬁt patients [19].
Several recent studies have suggested that intermediateintensity regimens with a 20% to 30% reduction in dose intensity could reduce toxicity without causing signiﬁcant increases
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in the risk of relapse or overall worse transplantation outcomes [20-22].
The cost and limited availability of radiation therapy in
many developing countries should not be a major obstacle,
because non-radiation-based conditioning regimens are available for nearly all diseases or conditions in which HSCT is indicated.
Blood Product Support
In adult recipients of autologous HSCT, 2 randomized trials
reported similar rates of bleeding with the use of a therapeutic
rather than a prophylactic strategy for platelet transfusion
[23,24]. Both American Society of Clinical Oncology and the
British Society of Haematology recommend the use of a therapeutic platelet transfusion strategy in the autologous HSCT setting, which results in less platelet use and substantial cost
savings [25,26]. In allogenic HSCT, a randomized study subgroup analysis found similar rates of bleeding at low platelet
doses (1.1 £ 1011) compared with medium (2.2 £ 1011) and
high (4.4 £ 1011) doses. This led to a decreased number of platelets transfused per patient at doses between 1.1 £ 1011 and
4.4 £ 1011 platelets/m2 with similar bleeding events [27]. Irradiated blood products should be used according to international guidelines.
Performing Autologous HSCT without Stem Cell
Cryopreservation
Cryopreservation of stem cells requires a relatively
advanced stem cell processing laboratory with mechanical,
controlled-rate freezers. Several reports have described the
feasibility of noncryopreserved G-CSF-mobilized whole blood
or autologous bone marrow (with or without previous administration of G-CSF). Stem cell graft containing blood units or
bone marrow can be stored brieﬂy in a standard blood bank
refrigerator at +4 °C until infusion [28-30].
Several centers have recently reported outcomes of autologous HSCT for multiple myeloma using noncryopreserved
stem cells without G-CSF support [31-34]. The success of this
technique depends on abbreviated conditioning, with 1 day
of high-dose melphalan for patients with multiple myeloma
and short-duration conditioning for patients with lymphoma. This technique precludes the need for costly cryopreservation and avoids the possible side effects from
infusion of DMSO for cryopreservation. These autologous
transplantation techniques were reported to yield early
engraftment and reduced hospital length of stay, with signiﬁcant cost savings. Outcomes were comparable to those from
conventional conditioning with cryopreserved stem cells in
patients with multiple myeloma [31-34]. Two recent studies
of noncryopreserved autografts from developing countries
using post-HSCT G-CSF also indicate comparable engraftment
rates to cryopreserved autografts [35,36].
Thus, given the evident safety and efﬁcacy of using noncryopreserved stem cells, a new HSCT center might not need
mechanical freezers in place for autograft cryopreservation.
Graft Source
Peripheral blood stem cells (PBSCs) are known to offer
more rapid neutrophil and platelet recovery compared with
bone marrow grafts, with an early cost reduction of approximately 30% compared with bone marrow in some studies
[37-39]. The use of PBSCs can lead to speciﬁc resource savings
in hospitalization, platelet transfusions, and use of growth
factors [40,41].
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Unlike in autologous HSCT, chronic GVHD is a serious late
complication of allogeneic HSCT that results in serious morbidity and mortality. Most studies have reported a higher incidence of chronic GVHD with the use of allogeneic PBSCs,
which may potentially offset the early cost savings. Appropriate selection of cases and developing well-informed indications for the use of PBSCs could reﬂect favorably on procedural
costs and transplantation outcomes [42].
In a recent study by the Center for International Blood and
Marrow Transplant Research (CIBMTR), the use of PBSCs
resulted in an acceptable alternative for transplanting patients
with aplastic anemia in developing countries, as PBSC grafts
were associated with faster engraftment, lower frequency of
infections, and a lower likelihood of graft rejection in heavily
pretransfused patients [43].
However, in autologous HSCT there is strong evidence of
clinical beneﬁt and cost savings using PBSCs which has been
consistently reported [44-47].
Alternative Donors and Graft Manipulation
The use of alternative donors, speciﬁcally HLA-compatible
unrelated donors (URD), has emerged as a signiﬁcant driver of
costs, even beyond the costs of stem cell procurement
[8,48,49]. Among the various sources of alternative donors,
myeloablative umbilical cord blood transplantation is associated with the highest costs, followed by matched URD. Accordingly, these donor sources should not be considered a priority
in developing countries for a new HSCT program.
The preferred and most cost-effective alternate donor
transplantation modality in developing countries may be a
related (family-member) haploidentical transplantation using
post-transplant cyclophosphamide (PTCy) for GVHD prevention. The posttransplant course, however, might require more
experience as conventional, URD HSCT.
Alternatives to PTCy for haploidentical transplantation
use different methods of T-cell depletion (TCD) of the donor
graft or other cellular manipulations, which are complex
and require advanced and costly stem cell processing technology [50].
Cost of Supportive Care Medications
Pharmacy costs range from 8% to 39% of the total expenditures related to HSCT. Hematopoietic growth factors, GVHD

prophylactic agents, and antimicrobials are the major contributors to pharmacy costs [51-53]. Several generic forms are
now available for ﬂuconazole and more recently for voriconazole as well [54]. This could help offset some costs, provided
that these alternative products demonstrate similar efﬁcacy.
Pharmacy costs are expected to continuously rise given the
changes in HSCT practice, with increasing use of newer immunosuppressive regimens and the higher cost of new anti-infective agents [52]. The long-term excess pharmacy costs for
patients with chronic GVHD who may require prolonged
immunosuppressive treatment are unpredictable and may be
large [52].
A biosimilar drug is a similar copy of an approved injectable
original biologic substance that may be available after the original patent protection has expired [55]. Because drugs are produced by cultured cells, small biological differences between
original and biosimilars may exist. Nonetheless, provided that
they are demonstrably as safe and efﬁcacious as the originator
product, the use of well-established biosimilars should be considered to aid in cost containment and to increase the availability of drugs needed for HSCT. If these biosimilars are
properly evaluated and their clinical effectiveness is proven,
their generally reduced costs may contribute to the long-term
ﬁnancial sustainability of HSCT programs [55-57]. Several biosimilars of G-CSF are less expensive alternatives to the original
brand product. The European Medicines Agency has recently
approved several biosimilar versions after the patent of the
original G-CSF brand expired in Europe in 2006 [55].
Several G-CSF biosimilars have been evaluated in the setting of stem cell mobilization for autologous HSCT. Results
show similar mobilization yields with comparable safety proﬁles as the originator G-CSF. Moreover, both myeloid and
platelet recovery times are similar to those of the originator GCSF product [56-62]. This noninferiority model could be
extrapolated to other medications, ultimately leading to significant cost savings. Highly reputable pharmaceutical companies
are already involved in the manufacturing process of several
biosimilar medications essential for HSCT [63]. Table 1
presents several currently approved biosimilars used in the
HSCT arena. The use of these biosimilars should be explored in
developing countries once local approvals are in place.
Beyond the costs of certain drugs, another major problem is
reliable availability. The experience in different countries and

Table 1
Some Biosimilars Approved in the United States and European Union Pertaining to HSCT*
Generic/Molecule

Biosimilar

Year Approved

Use in HSCT

Filgrastim

Tevagrastim
Ratiograstim
Filgrastim Hexal
Zarzio
Accoﬁl
Zarxio

2008 (EMA)
2008 (EMA)
2009 (EMA)
2009 (EMA)
2014 (EMA)
2015 (FDA)

Mobilization of peripheral stem cells for autologous HSCT

Rituximab

Truxima
Rixathon
Ritemvia

2017 (EMA)
2017 (EMA)
2017 (EMA)

Treatment of chronic GVHD

Inﬂiximab

Inﬂectra
Flixabi

2013 (EMA); 2016 (FDA)
2016 (EMA)

Treatment of acute GVHD

Etanercept

Benepali
Erelzi

2016 (EMA)
2016 (FDA); 2017 (EMA)

Treatment of acute GVHD
Treatment of BOS; treatment of IPS

Enoxaparin

Inhixa
Thorinane

2016 (EMA)
2016 (EMA)

DVT prophylaxis
DVT treatment

* The table lists only some of the approved biosimilars and is not intended to be inclusive of all approved biosimilars. The WBMT is working on a separate publication that will contain a complete list of approved biosimilars.EMA indicates European Medicines Agency; FDA, US Food and Drug Administration; BOS, bronchiolitis
obliterans syndrome; IPS, idiopathic pulmonary syndrome; DVT, deep venous thrombosis.
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continents underscores the need to check the availability and
approval of the essential drugs needed to perform HSCT. In
some countries, cyclosporine is only available orally but not
intravenously, busulfan may not be available at all, and importing needed drugs is sometimes very difﬁcult. The WBMT has
prepared a list of essential drugs that should be available for a
successful program. Licensing of drugs in a country may
depend on the demand, and some drugs needed for HSCT may
be used only for HSCT. Sometimes availability of drug needed
for HSCT will also improve the treatment of the underling disease before HSCT. Close interaction with national health
authorities is recommended to guide informed policies for speciﬁc drug availabilities.
Post-Transplantation Factors
Several post-transplantation factors may greatly increase
costs. Prolonged hospitalization and late complications are the
most signiﬁcant drivers of costs. Designing programs for posttransplantation care, including home health services and outpatient follow-up systems allowing safe follow-up either at
home or at a hostel where a well-trained and qualiﬁed nurse
can monitor patients who need less aggressive interventions,
have been found to reduce post-transplantation costs [64].
Socioeconomic and Other Factors
In many developing countries, many patients with acute
leukemia die before referral to a national or regional HSCT center. This indirectly leads to a relatively larger proportion of
HSCTs performed for non-neoplastic indications, such as bone
marrow failure and hemoglobinopathies, diseases more permissive of delays to HSCT. The time from diagnosis to HSCT is
likely to be longer in developing countries, with the resulting
unintended consequences of having sicker candidates present
for HSCT owing to advanced disease, poor performance status,
more infections, or transfusion alloimmunization. The consequences of delay may be higher costs and poorer outcomes of
HSCT. Efforts to shorten the time from diagnosis to HSCT
should be considered a priority in developing countries.
Increasing public awareness and patient education about
essential hygienic and infection control measures, as well as
utilization of social services, may also help educate patients
and caregivers about recommendations that will increase
HSCT success in developing countries.
The Human Development Index (HDI) is used by the United
Nations to evaluate a country’s socioeconomic achievements
based on 3 parameters: longevity, knowledge, and standard of
living [65]. The number of transplantations performed per unit
population, as well as early and long-term outcomes, are
directly related to the HDI [66-70].
Information Technology and Quality Benchmarks
The most effective way to improve HSCT outcomes is to
establish and maintain good quality programs in transplantation centers. Established databases deﬁne benchmarks for
error reduction and improvement of outcomes. It is desirable
for each HSCT center to have an internal database with experienced data managers and staff who can maintain the database
and report the data to global registries (eg, European Society
for Blood and Marrow Transplantation, Center for International
Blood and Marrow Transplant Research). Developments in artiﬁcial intelligence (AI) for some aspects of tertiary care center
management is predicted to lower costs. These may include
machine learning algorithms in medical billing, supply chain
management, scheduling efﬁciencies, virtual radiology (for
image interpretation), and prevention of readmissions [71-77].
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Because many AI companies are currently originating in developing countries, it may be valuable to explore the application
of AI systems at HSCT startup with the goal of cost reduction.
Telemedicine in Developing Countries
Currently available techniques allow intensive cooperation
with experienced centers. Pilot programs are currently active
worldwide. This approach is particularly valuable in settings
where a highly experienced HSCT program director is not
available. Important guidelines for success involve training of
local senior physicians, suitable facilities and laboratory capabilities, and regular communication with outside consultants.
CONCLUSION
Establishing an HSCT center in countries with limited
resources is a multistep endeavor requiring extensive ﬁnancial,
social, technical, and human resources and the involvement of
physicians, health authorities, politicians, nurses, and scientiﬁc
societies. In some countries, the main obstacle remains constrained resources and inexperience, which may lead to high
operating and maintenance costs and also may complicate the
initial organization of a program. The WBMT has outlined the
major drivers of costs for a HSCT program and has provided
general recommendations to help limit initial program costs.
New cost-effectiveness studies from developing countries for
each aspect of HSCT—conditioning type, GVHD management,
information technology systems implementation, graft source
and donor choice, laboratory testing, drug costs (and biosimilar
use), blood bank utilization (deﬁned thresholds for packed red
blood cell and platelet transfusion)—may be of particular value
in improving the safety and affordability of HSCT.
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